ライフサイエンスコーパス: insomnia

1 ng the most common cause of disrupted sleep (insomnia).

2 d a severe treatment-emergent adverse event (insomnia).

3 sychiatric disorders that may be linked with insomnia.

4 ars) and elderly (>/=65 years) patients with insomnia.

5 ts were fatigue, headache, nausea, rash, and insomnia.

6 ator, is the gold-standard drug for treating insomnia.

7 ng and alcohol drinking were associated with insomnia.

8 ep emerged as a robust signature of sleep in insomnia.

9 psy and, alternatively, antagonists to treat insomnia.

10 xin receptor antagonist for the treatment of insomnia.

11 eased sleep fragmentation resembling chronic insomnia.

12 ommended as first-line treatment for chronic insomnia.

13 studies were fatigue, headache, nausea, and insomnia.

14 a, with ISI scores lower than the cutoff for insomnia.

15 e for evaluation in the treatment of primary insomnia.

16 ntailored and fixed online information about insomnia.

17 orexin receptors is an effective therapy for insomnia.

18 clinical trials for the treatment of primary insomnia.

19 eep disorders of obstructive sleep apnea and insomnia.

20 the high prevalence of sleep disorders like insomnia.

21 e events were fatigue, headache, nausea, and insomnia.

22 e nausea, somnolence, tremor, akathisia, and insomnia.

23 choice for the nonpharmacologic treatment of insomnia.

24 good sleepers, insomnia symptoms, and DSM-IV insomnia.

25 gnitive, and pharmacologic interventions for insomnia.

26 circadian rhythm and associated sleep-onset insomnia.

27 iatric symptoms, was predictive of objective insomnia.

28 may also be beneficial for the treatment of insomnia.

29 behavioral and pharmacologic treatments for insomnia.

30 Scheinker syndrome (GSS), and fatal familial insomnia.

31 Asthma and rhinitis have been related to insomnia.

32 ppropriateness of these methods for treating insomnia.

33 on are important, treatable risk factors for insomnia.

34 cient to identify factors that contribute to insomnia.

35 iolytic and sedative and in the treatment of insomnia.

36 could be potentially useful in treatment of insomnia.

37 smoking (OR 1.71) also increased the risk of insomnia.

38 he gold standard for behavioral treatment of insomnia.

39 ussler-Scheinker syndrome and fatal familial insomnia.

40 oven in a representative sample with chronic insomnia.

41 roduce clinically meaningful improvements in insomnia.

42 eases suicidality because of improvements in insomnia.

43 ation of effective behavioral treatments for insomnia.

44 se effects were rash, pruritus, fatigue, and insomnia.

45 orexin receptor antagonist for treatment of insomnia.

46 ents included fatigue, headache, nausea, and insomnia.

47 ep, whereas reductions in excitability cause insomnia.

48 ts were anxiety (57.7%), stress (24.2%), and insomnia (10.2%).

49 placebo vs 18.17 [28.35] for ipilimumab) and insomnia (15.17 [22.53] vs 25.60 [29.19]).

50 g-related [DR] psychomotor hyperactivity and insomnia); 16 subjects with grade 3 or higher laboratory

51 -emergent adverse events were fatigue (48%), insomnia (19%), nausea (18%), and headache (16%).

52 e sleepiness (2.66 (2.34-3.01)), and regular insomnia (2.36 (2.11-2.64)), even after controlling for

53 Incidences of insomnia (2.9% v 0.4%; P < .02) and heartburn (8.1% v 3.

54 of the high co-occurrence of depression and insomnia, a novel way to reduce the risk of escalating d

55 was higher than the prevalence of subjective insomnia according to DSM-IV-validated questionnaires.

56 Treatment-emergent adverse events (eg, insomnia, akathisia, worsening of schizophrenia, headach

57 d the other with intermediate probability of insomnia alone.

58 oking and obesity, are also risk factors for insomnia among asthmatics.

59 elusions or hallucinations in the context of insomnia and a schizophrenia spectrum diagnosis were ran

60 nsistent evidence exists for associations of insomnia and circadian rhythm dysfunction with cognition

61 Internet users (aged 18-64 years) with insomnia and depression symptoms, but who did not meet c

62 RQOL), there is insufficient data evaluating insomnia and HRQOL in children.

63 s, hopelessness, restlessness and agitation, insomnia and impulsiveness as measured by the STOP task.

64 e examined whether individuals with probable insomnia and individual insomnia symptoms had greater en

65 Morningness is associated with insomnia and other sleep phenotypes; and is associated w

66 ited applicability to patients with comorbid insomnia and other sleep problems, and accuracy of estim

67 creased alanine aminotransferase, influenza, insomnia and peripheral oedema.

68 confidence intervals for sleep disturbance (insomnia and sleep duration) and risk of thyroid cancer.

69 72/rs14259 SNPs potential linkage to primary insomnia and sleep hours in T2D families.

70 an T2D families phenotyping them for primary insomnia and sleep hours per night.

71 1043307/rs14259 were tested for linkage with insomnia and sleep hours.

72 s in significant and durable improvements in insomnia and sleep quality.

73 c factors were similar in both the objective insomnia and the DSM-IV insomnia groups.

74 Insomnia and the inability to sleep affect people's heal

75 sociation between asthma, nasal symptoms and insomnia and to identify risk factors for sleep disturba

76 xant have shown promise for the treatment of insomnias and sleep disorders in several recent clinical

77 common cancer symptoms (depression, anxiety, insomnia) and whether these potential disparities modify

78 se, the presence of ascites, encephalopathy, insomnia, and depression.

79 with breast or prostate cancer), depression, insomnia, and fatigue.

80 d by 10% of LDX participants were dry mouth, insomnia, and headache.

81 ommon adverse events were fatigue, headache, insomnia, and nausea.

82 ommon adverse events were fatigue, headache, insomnia, and nausea.

83 topy, fatigue, excessive daytime sleepiness, insomnia, and only 0 to 3 nights of sufficient sleep had

84 verse events were fatigue, nausea, headache, insomnia, and rash.

85 uscle spasm, alcohol withdrawal, palliation, insomnia, and sedation as they allosterically modulate g

86 in both arms, along with a decrease in pain, insomnia, anorexia, and constipation in both arms.

87 d apathy), and additional features (fatigue, insomnia, anosmia, hypersalivation and rapid-eye-movemen

88 s hyperactive neurological disorders such as insomnia, anxiety and epilepsy.

89 leepiness (aOR, 1.81; 95% CI, 1.28-2.55), or insomnia (aOR, 1.74; 95% CI, 1.28-2.37) had higher rates

90 long-term efficacy of pharmacotherapies for insomnia are not known.

91 between eczema and fatigue, sleepiness, and insomnia as predictors of poorer overall health status,

92 The prevalence of objective insomnia assessed by polysomnography was higher than the

93 The primary efficacy outcomes were insomnia assessed by the Insomnia Severity Index (ISI) a

94 The most common adverse events were fatigue, insomnia, asthenia, and headache.

95 The questionnaire included questions on insomnia, asthma, rhinitis, weight, height, tobacco use

96 FFI is manifested by sleep disturbances with insomnia, autonomic disorders and spontaneous and evoked

97 Clinicians should recognize insomnia because of its effects on function and health.

98 Clinicians may be reluctant to address insomnia because of its many potential causes, unfamilia

99 ll, DTG is well tolerated, with headache and insomnia being the most frequently reported adverse even

100 arenicline, 25% [511 of 2016 participants]), insomnia (bupropion, 12% [245 of 2006 participants]), ab

101 uately sensitive (36%) to identify objective insomnia, but were adequately specific (77%) to rule out

102 Patients aged 18 years or older with primary insomnia by DSM-IV-TR criteria were assigned using a com

103 Chronic insomnia can be a symptom of many medical, neurological,

104 Family and twin studies confirm that chronic insomnia can have a genetic component (heritability coef

105 der in whom cognitive behavioral therapy for insomnia (CBT-I) alone was unsuccessful.

106 Purpose Cognitive behavioral therapy for insomnia (CBT-I) and Tai Chi Chih (TCC), a movement medi

107 nts receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic in

108 inferior to cognitive behavioral therapy for insomnia (CBT-I) for the treatment of insomnia in patien

109 Although cognitive behavior therapy for insomnia (CBT-I) has been established as the first-line

110 Cognitive behavioral therapy for insomnia (CBT-I) improved posttreatment global and most

111 approaches, cognitive behavioral therapy for insomnia (CBT-i) is now commonly recommended as first-li

112 Although cognitive behavioral therapy for insomnia (CBT-I) is the treatment of choice in the gener

113 assigned to cognitive-behavioral therapy for insomnia (CBT-I), tai chi chih (TCC), or sleep seminar e

114 as part of cognitive-behavioral therapy for insomnia (CBT-I).

115 treated by cognitive behavioral therapy for insomnia (CBT-I).

116 Among older adults with insomnia, CBT-I reduced systemic inflammation, TCC reduc

117 to the already existing indications, such as insomnia, circadian sleep disorders, and depression, new

118 associations or mechanisms for personality, insomnia, cognitive stimulation and social activities, h

119 Studies of insomnia comorbid with medical, sleep, or psychiatric di

120 Insomnia complaints are common in older adults and may b

121 inflammatory biology dynamics; the impact of insomnia complaints, extremes of sleep duration, and exp

122 e most frequent adverse events reported were insomnia, decreased appetite, nausea, and dry mouth.

123 roportion of patients with cirrhosis exhibit insomnia, delayed sleep habits, and excessive daytime sl

124 e role of REM sleep in emotion regulation in insomnia, depression, and posttraumatic stress disorder.

125 Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in significant

126 recommendations on the management of chronic insomnia disorder in adults.

127 armacological therapy in adults with chronic insomnia disorder in whom cognitive behavioral therapy f

128 The prevalence of insomnia disorder is approximately 10% to 20%, with appr

129 ublished in English and enrolled adults with insomnia disorder lasting 4 or more weeks.

130 rm global and sleep outcomes for adults with insomnia disorder, but the comparative effectiveness and

131 vioral interventions are frequently used for insomnia disorder.

132 logic interventions are often prescribed for insomnia disorder.

133 (CBT-I) as the initial treatment for chronic insomnia disorder.

134 ient population includes adults with chronic insomnia disorder.

135 to offer a comprehensive explanation to the insomnia exhibited by these patients.

136 The most common adverse events (AEs) were insomnia, fatigue, and headache.

137 , familial CJD (gCJD) n = 17, fatal familial insomnia (FFI) n = 9, Gerstmann-Straussler-Scheinker syn

138 well as lab tests in Chinese fatal familial insomnia (FFI) subjects.

139 of a different prion disease [fatal familial insomnia (FFI)].

140 This issue provides a clinical overview of Insomnia focusing on prevention, diagnosis, treatment, p

141 n both the objective insomnia and the DSM-IV insomnia groups.

142 nders were controlled for, men with probable insomnia had a mean higher consumption of 35.8 kcal/d (9

143 Children reporting ICSD2-derived insomnia had lower HRQOL.

144 (CBT)-the best evidence-based treatment for insomnia-has not been tested in this patient population.

145 underlying hyperarousal, the key symptom of insomnia, have remained elusive, hampering cause-targete

146 The most common adverse events were fatigue, insomnia, headache, and nausea.

147 s between subjects with and without probable insomnia in 2004 and also across categories for each ins

148 xamined the HRQOL and health associations of insomnia in a longitudinal cohort of 194 children (96 gi

149 Insomnia in children is associated with worsened HRQOL a

150 43307/rs14259 (E197G-A>G) SNPs are linked to insomnia in our Italian families.

151 safe and efficacious procedures for treating insomnia in patients with bipolar disorder.

152 py for insomnia (CBT-I) for the treatment of insomnia in patients with cancer.

153 is noninferior to CBT-I for the treatment of insomnia in survivors of breast cancer.

154 with standard care, CBT led to reductions in insomnia in the large effect size range at week 12 (adju

155 imed to describe the objective prevalence of insomnia in the Sao Paulo, Brazil, Epidemiologic Sleep S

156 sed, automated CBT-I intervention to improve insomnia in the short term (9 weeks) and long term (1 ye

157 leep phase disorder (DSPD), a common form of insomnia in which sleep episodes are shifted to later ti

158 group, and 18 in the opicapone 50 mg group), insomnia (in one, seven, two, seven, and seven patients,

159 The risk of insomnia increased with the severity of asthma, and the

160 Insomnia increases type-2 diabetes (T2D) risk.

161 Sleep disturbances including insomnia independently contribute to risk of inflammator

162 f escalating depression might be to offer an insomnia intervention.

163 The etiology and pathophysiology of insomnia involve genetic, environmental, behavioral, and

164 ithout RBV, respectively, including fatigue, insomnia, irritability, and rash/pruritus.

165 It provides strong evidence that insomnia is a causal factor in the occurrence of psychot

166 Insomnia is a common clinical condition characterized by

167 Insomnia is a distressing and often persisting consequen

168 Fatal familial insomnia is a rare disease caused by a D178N mutation in

169 Insomnia is a risk factor for impaired function, develop

170 Probable insomnia is associated with higher intakes of total ener

171 Insomnia is associated with increased risk for suicide.

172 Insomnia is associated with several adverse health outco

173 Insomnia is common in children, and is associated with d

174 Chronic insomnia is defined by difficulties in falling asleep, m

175 The diagnosis of insomnia is established by a thorough history of sleep b

176 Although adult insomnia is linked to worsened health-related quality of

177 markers of inflammation in older adults with insomnia is not known.

178 Insomnia is one of the most prevalent health concerns in

179 patients were sleep disturbances, including insomnia, laryngeal stridor, sleep breath disturbance, a

180 We aimed to determine whether treating insomnia leads to a reduction in paranoia and hallucinat

181 Pharmacotherapies for insomnia may cause cognitive and behavioral changes and

182 ing research is testing whether treatment of insomnia may reduce suicidality in adults with depressio

183 uded sleep disturbances (eg, sleep apnea and insomnia), mental health status (eg, posttraumatic stres

184 Our findings show that CBT for insomnia might be highly effective for improving sleep i

185 ropenia (n=2 [5%]), hypertension (n=2 [5%]), insomnia (n=1 [2%]), tinnitus and dizziness (n=1 [2%]),

186 3755 participants to receive digital CBT for insomnia (n=1891) or usual practice (n=1864).

187 sts, including excessive daytime sleepiness, insomnia, narcolepsy, rapid eye movement sleep behavior

188 han did the nicotine patch for vivid dreams, insomnia, nausea, constipation, sleepiness, and indigest

189 ommon adverse events were headache, fatigue, insomnia, nausea, rash, and anemia.

190 orting a new medical condition (intermittent insomnia odds ratio 5.9 [95% CI 1.3-26.7, p = 0.04], per

191 5.9 [95% CI 1.3-26.7, p = 0.04], persistent insomnia odds ratio 8 [95% CI 2.3-27.7, p = 0.001]).

192 of sleep disturbance, sleep restriction, and insomnia on (a) antiviral immune responses with conseque

193 n; and the influence of sleep complaints and insomnia on inflammaging and molecular processes of cell

194 he efficacy of CBT-I or independently affect insomnia or sleep quality.

195 Infection, hypotension, hyponatremia, insomnia or stress, and benzodiazepine use were higher d

196 ital cognitive behavioural therapy (CBT) for insomnia or usual care, and the research team were maske

197 m based on cognitive behavioural therapy for insomnia, or HealthWatch, an interactive, attention-matc

198 eptor antagonist shown to be efficacious for insomnia over 3 months.

199 The primary outcome measures were for insomnia, paranoia, and hallucinatory experiences.

200 e neurophysiology of sleep disorders such as insomnia, parasomnias, and narcolepsy is still evolving.

201 nt clinical trials in volunteers and primary insomnia patients.

202 Psychophysiological insomnia (PI) includes arousal to sleep-related stimuli

203 obutyric acid (GABA) in both MDD and primary insomnia (PI).

204 ciated with neurovegetative symptoms such as insomnia, poor appetite and fatigue, but not sadness, wo

205 to receive SHUTi, a 6 week, modular, online insomnia program based on cognitive behavioural therapy

206 aimed to assess whether an online self-help insomnia program could reduce depression symptoms.

207 tests, fatigue, nausea, headache, dizziness, insomnia, pruritus, rash, and vomiting.

208 for interview to assess quality of sleep and Insomnia (PSQI score >5).

209 a validated 5-item Women's Health Initiative Insomnia Rating Scale.

210 ty trial involving patients with cancer with insomnia recruited from a tertiary cancer center in Calg

211 Whether treatments that target insomnia-related complaints might reverse these markers

212 Insomnia remains a common problem among asthmatics.

213 Insomnia remains under-diagnosed and poorly treated desp

214 For secondary outcomes, insomnia remission was 46.2% and 37.9% in CBT-I and TCC,

215 The significant association between insomnia score and thyroid cancer was confined to nonobe

216 Insomnia score was measured using a validated 5-item Wom

217 or potential confounders, women with greater insomnia scores had a significantly higher risk of thyro

218 onclusion, postmenopausal women with greater insomnia scores, especially nonobese women, had a signif

219 Altogether, 303 adults with chronic insomnia self-referred to participate, of whom 151 (49.8

220 period, the most common adverse events were insomnia (seven [3%] of 201 patients allocated extended-

221 of distress lasting overnight increased with insomnia severity (beta = 0.29, P < 10(-23)), whereas sh

222 utcomes were self-reported online ratings of insomnia severity (Insomnia Severity Index) and online s

223 MBSR was inferior to CBT-I for improving insomnia severity immediately after the program (P = .35

224 icacy outcomes were insomnia assessed by the Insomnia Severity Index (ISI) and delusions and hallucin

225 sk factors and working hours, as well as the Insomnia Severity Index (ISI), a validated instrument fo

226 for all variables, favoring the SHUTi group (Insomnia Severity Index [F3,1063 = 20.65, P < .001], sle

227 Insomnia was assessed by the Insomnia Severity Index and sleep quality by the Pittsbu

228 re maintained at the 1-year follow-up (SHUTi Insomnia Severity Index d = 2.32 [95% CI, 2.01-2.63], sl

229 emed treatment responders at 1 year based on Insomnia Severity Index data.

230 eported online ratings of insomnia severity (Insomnia Severity Index) and online sleep diary-derived

231 eriority margin was 4 points measured by the Insomnia Severity Index.

232 oups had significantly greater reductions in insomnia severity postintervention than the P group, wit

233 Insomnia severity was associated with hyperarousal (beta

234 system with minimisation to balance for sex, insomnia severity, and psychotic experiences, to receive

235 ants (n = 1,199) completed questionnaires on insomnia severity, hyperarousal, self-conscious emotiona

236 he phenotype determination of sporadic fatal insomnia (sFI) and a subtype of sporadic Creutzfeldt-Jak

237 hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity d

238 esity, Parkinson's disease, global polyuria, insomnia, sleep disturbances, heart failure, anxiety, an

239 utcomes were clinician-assessed remission of insomnia; sleep quality; total sleep time, sleep onset l

240 in 2004 and also across categories for each insomnia symptom while adjusting for related covariates.

241 We discover loci associated with insomnia symptoms (near MEIS1, TMEM132E, CYCL1 and TGFBI

242 4.5 +/- 7.1 years of age) with assessment of insomnia symptoms (restlessness, difficulty falling asle

243 on analyses of self-reported sleep duration, insomnia symptoms and excessive daytime sleepiness in th

244 Insomnia symptoms are associated with vulnerability to a

245 n-based study of women in the United States, insomnia symptoms are implicated in accelerated aging.

246 both asthma and nasal congestion, 55.8% had insomnia symptoms compared with 35.3% in subjects withou

247 , we prospectively examined whether men with insomnia symptoms had an increased risk of mortality dur

248 iduals with probable insomnia and individual insomnia symptoms had greater energy intake and a lower

249 low-Up Study and free of cancer, reported on insomnia symptoms in 2004, were followed through 2010.

250 nals Follow-Up Study reported information on insomnia symptoms in 2004.

251 The subjective prevalence of insomnia symptoms was 45%, and the subjective prevalence

252 The prevalence of insomnia symptoms was significantly higher among asthmat

253 Insomnia symptoms were also associated with more late di

254 Insomnia symptoms were related to advanced epigenetic ag

255 as categorized into 3 groups: good sleepers, insomnia symptoms, and DSM-IV insomnia.

256 Some insomnia symptoms, especially difficulty initiating asle

257 For individual insomnia symptoms, nonrestorative sleep and a difficulty

258 i Chih (TCC), a movement meditation, improve insomnia symptoms.

259 order who underwent behavioral treatment for insomnia, the authors found that regularizing bedtimes a

260 e events were headache, fatigue, nausea, and insomnia; the overall rate of discontinuation of sofosbu

261 tion for the millions of adults with chronic insomnia, there is a paucity of trained clinicians to de

262 d the potential of interventions that target insomnia to reverse inflammation, are also reviewed.

263 onset lasting >30 minutes (sleep maintenance insomnia), total sleep time <360 minutes and a terminal

264 Online cognitive behaviour therapy for insomnia treatment is a practical and effective way to r

265 understand the potential salutary effects of insomnia treatment on inflammation, with implications fo

266 ing agent armodafinil (A), results in better insomnia treatment outcomes in cancer survivors than CBT

267 The proportion of participants who showed insomnia treatment response at 15 months was 43.7% and 4

268 Primary outcome was insomnia treatment response-that is, marked clinical imp

269 Insomnia treatments include benzodiazepines, benzodiazep

270 ts high caffeine content) including anxiety, insomnia, tremulousness, and palpitations, as well as bo

271 inically useful behavioral interventions for insomnia, typically delivered as part of cognitive-behav

272 aumatic Stress Disorder (PTSD) patients with insomnia under a yoga training regime.

273 onset latency >30 minutes (sleep initiating insomnia), wake after sleep onset lasting >30 minutes (s

274 45%, and the subjective prevalence of DSM-IV insomnia was 15%.

275 severity of asthma, and the adjusted OR for insomnia was 2.65 in asthmatics with three symptoms comp

276 While the overall prevalence of insomnia was 26.6%, and little difference was found betw

277 < 0.001) and the estimates of prevalence of insomnia was 29.4% in the rural areas, significant highe

278 The prevalence of objective insomnia was 32%.

279 Insomnia was a mediator of change in paranoia and halluc

280 Insomnia was assessed by the Insomnia Severity Index and

281 Persistent ICSD2-derived insomnia was associated with an increased risk of report

282 Additionally, the presence of insomnia was associated with an increased risk of report

283 ociated with fatigue, daytime sleepiness, or insomnia was associated with even higher odds of obesity

284 studies suggested that use of hypnotics for insomnia was associated with increased risk for dementia

285 s, 4th edition (DSM-IV) criteria, subjective insomnia was categorized into 3 groups: good sleepers, i

286 Objective insomnia was defined by meeting 1 of the following crite

287 ciation between these key characteristics of insomnia was mediated specifically by reduced overnight

288 ore common in the EFV-TDF-FTC group, whereas insomnia was reported more frequently in the DTG-ABC-3TC

289 ep Disorders, second edition (ICSD2) derived insomnia was seen intermittently in 27% of children, and

290 Insomnia was the most frequent adverse event (17.3%) ass

291 iprazine-treated patients were akathisia and insomnia; weight gain was slightly higher with cariprazi

292 Symptoms of insomnia were associated with increased epigenetic age o

293 University students with insomnia were randomly assigned (1:1) with simple random

294 this randomized trial, 123 older adults with insomnia were randomly assigned to cognitive-behavioral

295 Melancholic patients experience anorexia and insomnia, whereas atypical patients experience hyperphag

296 hat involved survivors of breast cancer with insomnia who were recruited from the Los Angeles communi

297 utes and a terminal wakefulness >30 minutes (insomnia with too short duration of sleep or early morni

298 effective treatment for adults with chronic insomnia, with clinically meaningful effect sizes.

299 1 year of nightly treatment in patients with insomnia, with efficacy noted for subjective measures of

300 receiving standard care alone no longer had insomnia, with ISI scores lower than the cutoff for inso